Sofinnova Partners unveils Sofinnova.AI: A cutting-edge artificial intelligence platform set to transform its life sciences investment practice
Combination of real time scientific databases with proprietary data will enable venture capital firm to enhance deal origination and portfolio growth through data-driven insights and strengthened entrepreneurial partnerships
PARIS, France – December 5, 2023 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the launch of Sofinnova.AI, an artificial intelligence platform that seamlessly integrates advanced computational capabilities with the firm’s 50-year-history of industry expertise, one of the world’s largest, longitudinal, annotated, proprietary data sets on early-stage life science companies, enabling unprecedented insights into life sciences innovation discovery.
